In this study, it was found that about 34% of Chinese bone tumor patients harbored actionable targeted mutations, including CDKN2A, PTEN, FGFR1/2/3, NF1, and NTRK1/2/3. This evidence concerns the gene FGFR1 and bone neoplasm.